NLS Pharmaceutics Ltd. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2019 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
NLS Pharmaceutics Ltd. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2019 to Q4 2023.
  • NLS Pharmaceutics Ltd. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $4.6M, a 22.7% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $4.6M +$852K +22.7% Dec 31, 2023 20-F 2024-05-15
Q4 2022 $3.75M +$1M +36.6% Dec 31, 2022 20-F 2024-05-15
Q4 2021 $2.75M +$1.12M +68.9% Dec 31, 2021 20-F 2023-05-05
Q4 2020 $1.63M +$384K +31% Dec 31, 2020 20-F 2022-03-24
Q4 2019 $1.24M Dec 31, 2019 20-F 2021-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.